Amgen 2006 Annual Report Download - page 37

Amgen 2006 Annual Report 35
Amgen Inc. Corporate Office
One Amgen Center Drive
Thousand Oaks, California 91320-1799
[phone]
Amgen 2006 Annual Report Summary
and Availability of SEC Form 10-K
This information is a summary and does not provide complete
information; it should be considered along with the Company’s
Annual Report on Form 10-K for the year ended December 31,
2006. A copy of the Company’s Form 10-K for the year ended
December 31, 2006, filed with the Securities and Exchange
Commission, is available without charge, upon written request to
Investor Relations, Amgen, One Amgen Center Drive, Thousand
Oaks, California 91320-1799, by calling (800) 84-AMGEN or by
accessing the Company’s website at www.amgen.com.
Transfer Agent and Registrar
American Stock Transfer & Trust Company
59 Maiden Lane
New York, New York 10038
Stockholder Inquiries
Inquiries related to stock transfers or lost certificates should
be directed to American Stock Transfer & Trust Company,
[phone] or [phone] (www.amstock.com).
General information regarding the Company and recent news
releases can be obtained by contacting Amgen’s automated
stockholder information line at (800) 84-AMGEN or by accessing
the Company’s website at www.amgen.com.
Independent Registered Public Accounting Firm
Ernst & Young LLP
Los Angeles, California
Annual Meeting
The Annual Meeting will be held on Wednesday, May 9, 2007,
at 10 a.m. at the Westin Providence Hotel, One West Exchange
Street, Providence, Rhode Island 02903.
Price Range of Common Stock
The Company’s common stock trades on the NASDAQ Stock
Market under the symbol AMGN. No cash dividends have been
paid on the common stock to date, and the Company currently
intends to retain any earnings for development of the Company’s
business and for repurchases of its common stock.
The following table sets forth, for the fiscal periods indicated,
the range of high and low closing sales prices of the common
stock as quoted on the NASDAQ Stock Market for the years
2006 and 2005:
2006 2005
High Low High Low
4th Quarter $ 76.50 $ 68.31 $ 84.42 $ 73.37
3rd Quarter 72.14 63.92 86.17 60.86
2nd Quarter 72.86 63.94 63.18 57.20
1st Quarter 80.36 71.01 64.87 57.98
Trademarks Listed in This Report
Amgen, Aranesp® , EPOGEN® , Kepivance™ , Kineret® ,
Mimpara® , Neulasta® , NEUPOGEN® , Sensipar® , Vectibix™ ,
Enbrel® , XenoMouse® , and Avimer™ are trademarks of
Amgen Inc. or its wholly owned subsidiaries.
Hotlines
Customer Service Hotline (800) 28-AMGEN
Investor Materials Hotline (800) 84-AMGEN
Jobline [phone]
Medical Information (800) 77-AMGEN
Reimbursement Hotline [phone]
Stockholder Information
Thanks to the patients, health care professionals, partners and staff members who appear in this Annual Report for giving their valuable time and support.
The paper utilized in the printing of the Amgen 2006 Annual Report contains a mix of pulp that is derived from Forest Stewardship Council (FSC)-certified well-managed forest
and 10 percent post-consumer recycled paper fibers. The FSC promotes environmentally appropriate, socially beneficial and economically viable management of the world’s forests.
Amgen employed Cenveo Anderson Lithograph, an environmentally sustainable printer, for the production of this Annual Report. Cenveo Anderson Lithograph is FSC-certified; has a zero-land-
fill, 100 percent recycling policy for all hazardous and non-hazardous production waste by-products; generates all its own electrical and thermal power; and is the only Air Quality Management
District (AQMD)-certified totally enclosed commercial print facility in the nation, which results in virtually zero volatile organic compound (VOC) emissions from its production operations being
released into the atmosphere.